MannKind Corporation (MNKD) Reveals 2026 Growth Drivers

Core Insights - MannKind Corporation (NASDAQ:MNKD) is identified as a stock with high potential under $10, with significant growth drivers anticipated for 2026 [1] Financial Performance - The company closed fiscal 2025 with record fourth quarter revenue exceeding $100 million, indicating strong financial performance [2] Regulatory Milestones - The FDA is expected to provide updates on the Afrezza label on January 23, which aims to simplify dosing for patients transitioning from injectable rapid-acting insulin, potentially increasing adoption among adults with diabetes [2] - A supplemental Biologics License Application (sBLA) for Afrezza has a PDUFA target date of May 29, 2026, which, if approved, would introduce the first needle-free insulin for pediatric patients [3] - The FDA is also anticipating a supplemental New Drug Application (sNDA) for the FUROSCIX ReadyFlow Autoinjector, with a PDUFA date of July 26, 2026, which would enable the delivery of an 80 mg/ml IV-equivalent diuretic dose in under 10 seconds if approved [3] Analyst Ratings - Wall Street analysts are optimistic about the stock, with Gregory Renza from Truist Financial reiterating a Buy rating on January 13, and Brandon Folkes from H.C. Wainwright also maintaining a Buy rating with a price target of $11 on January 9 [4] Company Overview - MannKind Corporation is a biopharmaceutical company focused on developing and commercializing innovative therapeutic devices and products for serious unmet medical needs in endocrine and orphan lung diseases. Its product pipeline includes Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501 [5]